For information on this past event please contact Meetings Management

POSTER SESSION

Poster 1
‘Renewed interest in mucosal BCG vaccination’
Nathalie Winter (Pasteur Institute, Paris, France)

Poster 2
‘Exploiting the ability of mycobacterial mammalian cell entry protein (mce1A) to alter the immune response against a subunit vaccine’
Claus Aagaard, Jes Dietrich and Peter Andersen (Statens Serum Institut, Copenhagen, Denmark)

Poster 3
‘Characterization of a novel adjuvant based on cationic lipsomes suitable for use in TB vaccines’
Else Marie Agger, Karen Korsholm, Dennis Christensen, Ida Rosenkrands and Peter Andersen (Statens Serum Institut, Copenhagen, Denmark)

Poster 4
‘Supplementing BCG with additional antigens increases the protection against M. tuberculosis’
Jes Dietrich and Peter Andersen (Statens Serum Institut, Copenhagen, Denmark)

Poster 5
‘Construction of a state-of-the-art facility for BCG manufacture that will use fermentation technology for vaccine production’
Manoj Kole et al. (Aeras Global TB Vaccine Foundation, Bethesda, Maryland, USA)

Poster 6
‘Post exposure vaccination in mouse models for latent M. tuberculosis infection’
Carina V. Lundberg, Anneline Nansen, Jes Dietrich and Peter Anderson (Statens Serum Institut, Copenhagen, Denmark)

Poster 7
‘CpG oligodeoxynucleotides induce two distinct signalling pathways mediated by Ca⁺⁺ – dependent phospholipase D and Ca⁺⁺ -independent phospholipase A₂ leading to mycobacterial activity in monocytes’
Maurizio Fraziano et al. (University of Rome ‘Tor Vergata’, Rome, Italy)

Poster 8
‘Short-period chemotherapy against latent TB is feasible when combined with RUTI therapeutic vaccination’
Pere-Joan Cardona (Universitat Autonoma de Barcelona, Barcelona, Spain)

Poster 9
‘TB endpoints for the DARDAR prime-boost TB vaccine trial’
Robert D. Arbeit, Lisa Adams, C. Robert Horsburgh, C. Fordham von Reyn (Paratek Pharmaceuticals Inc., Boston, Massachusetts, USA)

Poster 10
‘Development of a post-exposure model in mice to evaluate the safety of new TB vaccines’
Steven C. Derrick (CBER/FDA, Bethesda, Maryland, USA)

Poster 11
‘DNAhsp65 vaccine: State of the art’
Helena F. Lopes et al. (Brazilian TB Research Network, University of Sao Paulo, Brazil)

Poster 12
‘Role of Mw vaccine in management of hydropneumothorax as an adjuvant to ATT (Anti Tuberculosis Therapy) with ICTD (Inter Costal Tube Drainage)’
Arun Maseeh et al. (Cadila Corporate campus, Ahmedabad, India)

Poster 13
‘Preliminary evaluation of a gamma-interferon test as alternative assay to determine the potency of Purified Protein Derivative (PPD) of Mycobacterium bovis tuberculins’
Rosanna Adone et al. (Istituto Superiore de Sanita, Rome, Italy)

Poster 14
‘Quality control of BCG: Estimation of viable count in lyophilised BCG vaccine by rapid assay of ATP’
Sten E. Jensen et al. (Statens Serum Institut, Copenhagen, Denmark)

Poster 15
‘Can Mycobacterium tuberculosis subvert innate immunity?
Vijaya Satchidanandam and Monali Mohan Bhate (Indian Institute of Science, Bangalore 560012, India)

Poster 16
‘The evaluation of protective efficacy of tuberculosis DNA vaccines with different dosage and by codelivery of cytokine plasmid’
Xueqiong Wu et al. (Tuberculosis Research Center, Beijing, China)

Poster 17
‘Establishment of an aerosol infection model of human tuberculosis for vaccine evaluation in two species of non-human primates’
S. Sharpe et al. (Health Protection Agency, Porton Down, Salisbury, UK)

Poster 18
‘Post exposure vaccination strategies - Modelling risk’
Donna Bryan and K. Barry Walker (NIBSC, Potters Bar, South Mimms, UK)

Poster 19
‘Studies of the Bulgarian BCG vaccine’
M. Chouchkova and T. Stefanova (BB-NCIPD, Sofia, Bulgaria)

Poster 20
‘Clinical usefulness of ‘dot’ immunoblotting, ELISA and fluorescent antibodies assays as diagnostic tools in paediatric tuberculosis’
Henriette Stavri et al. (National Research Institute for Microbiology and immunology, Bucharest, Romania)

Poster 21
‘Mycobacterium bovis BCG vaccination modulates TNF-α production after pulmonary challenge with virulent Mycobacterium tuberculosis in guinea pigs’
Toshiko Yamamoto et al. (Texas A&M University, College Station, Texas, USA)

Poster 22
‘Complement cascade should be integrated into the novel TB vaccine R&D’
Jian-Ping Xie et al. (Southwest China University, Chonqing, China)

Poster 23
‘Preliminary characterisation of mycobacterial heat shock proteins eliciting protection against infection with M. tuberculosis’
James Keeble et al. (NIBSC, Potters Bar, South Mimms, UK)

Poster 24
‘Investigation of mycobacterial antigens recognised by intravenous immunoglobulin’
Belinda M. Dagg et al. (NIBSC, Potters Bar, South Mimms, UK)

Poster 25
‘The use of a rabbit CNS infection model for evaluation of new antituberculosis vaccines’
Liana Tsenova et al. (PHRI, Newark, New Jersey, USA)

Poster 26
‘Mucosal immunization including oral prime with Mycobacterium bovis BCG and intranasal boost with the antigen 85B-ESAT-6 hybrid 1 fusion protein is more protective than BCG alone against tuberculosis’
Nathalie Winter et al. (Institut Pasteur, Paris, France)

Poster 27
‘Experimental nonhuman primate model for Mycobacterium tuberculosis infection in ABSL-III facility in China’
Zhongming Li et al. (Shanghai H&G Biotechnology Co. Inc., Shanghai, China)

Poster 28
‘Intranasal IFNγ and anti α-crystallin IgA inhibit Mycobacterium tuberculosis lung infection in mice’
Rajko Reljic et al. (King’s College London, London, UK)

Poster 29
‘Phase 1 clinical trial of oral BCG Moreau RdJ as booster TB vaccine’
Catherine Cosgrove et al. (St. George’s Hospital Medical School, London, UK)

Poster 30
‘Short-period chemotherapy combined with immunotherapy with RUTI is useful in the treatment against Mycobacterium bovis naturally infected goats’
Pere-Joan Cardona et al. (Universitat Autonoma de Barcelona, Spain)

Poster 31
‘Diagnosis of tuberculosis using T-SPOT . TB’
A. O’Keeffe et al. (Oxford Immunotec Ltd, Abingdon, Oxon, UK)

Poster 32
‘Regulatory CD4+ T cells induced by newborn vaccination with BCG’
Joanne Riley et al. (University of Cape Town, South Africa)

Poster 33
‘Immunogenicity testing of new potential vaccine targets against Mycobacterium tuberculosis by whole blood assay in a population with high TB prevalance’
Gerhard Walzl et al. (Stellenbosch University, Tygerberg, South Africa)

Poster 34
‘Immunogenicity of a novel TB vaccine, MVA85A, in a phase I/II trial in Cape Town, South Africa’
Sebastian J. Gelderbloem et al. (University of Cape Town, South Africa)

Poster 35
‘M. africanum as a model of strain effects with relevance to vaccine design’
Bouke de Jong et al. (Medical Research Council, The Gambia)

Poster 36
‘Regulatory T cells induced by environmental mycobacteria: effects on the BCG response’
G.T. Seah et al. (National University of Singapore, Singapore)

Poster 37
‘Vaccination of badgers (Meles meles) with BCG: Protective immunity against pulmonary challenge with M. bovis’
E. Gormley et al. (University College Dublin, Dublin, Ireland)

Poster 38
‘Differential effects of TNF blockade on TB-induced genes and cytokines’
Robert S. Wallis (PPD, Washington DC, USA)

Poster 39
‘Immunogenicity of DNA vaccines encoding Ag85A of Mycobacterium tuberculosis combined with wild type or mutated chimeric caspase C2P-9CSP3’
Tatiana Gartner et al. (Vrije Universiteit Brussels, Belgium)

Poster 40
‘Immunological studies DNA-vaccine encoded ESAT6 antigen’
O. Nosareva et al. (Vector, Novosibirsk Region, Russia)